These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24782318)

  • 1. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
    Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
    Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy.
    Wu J; Nie J; Luan Y; Ding Y
    Curr Med Chem; 2023; 30(20):2267-2311. PubMed ID: 36043742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
    Giannini G; Cabri W; Fattorusso C; Rodriquez M
    Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors: a patent review (2009 - 2011).
    Carafa V; Miceli M; Altucci L; Nebbioso A
    Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
    Li X; Xu W
    Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
    Feng W; Zhang B; Cai D; Zou X
    Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
    Gryder BE; Sodji QH; Oyelere AK
    Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment.
    Papavassiliou KA; Papavassiliou AG
    Expert Opin Investig Drugs; 2014 Mar; 23(3):291-4. PubMed ID: 24205827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of HDACs--effective drugs against cancer?
    Müller S; Krämer OH
    Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.
    Zhou N; Xu W; Zhang Y
    Drug Discov Ther; 2015 Jun; 9(3):147-55. PubMed ID: 26193935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.